Start with a goal,
not a molecule.
Patients rarely walk in asking for a specific peptide. They walk in wanting to lose weight, sleep better, recover faster, or feel like themselves again. Below, each major clinical goal is matched to the peptides with the strongest evidence for it.
Metabolic & weight management.
Sustained weight loss, insulin sensitivity, visceral fat, and metabolic markers that stop responding to diet and exercise alone.
Peptides we work with: Semaglutide, Tirzepatide, Retatrutide (investigational), AOD-9604, MOTS-c.
The GLP-1 class has changed metabolic medicine. Tirzepatide, which adds GIP agonism, has shown greater effect sizes than semaglutide in head-to-head work. Selection between them depends on tolerability, comorbidities, insurance coverage, and the specific metabolic picture lab work reveals.
What to expect: Titration over 4–8 weeks, monthly follow-up for the first quarter, lab review at 90 days.
Metabolic Reset Program →Recovery & injury repair.
Tendinopathy, post-surgical healing, slow-to-resolve soft-tissue injury, and gut lining repair.
Peptides we work with: BPC-157, TB-500 (thymosin beta-4), GHK-Cu.
Preclinical evidence for BPC-157 in tendon and soft-tissue models is strong. Human evidence is thinner but practitioner experience is consistent. We prescribe short, targeted cycles rather than continuous use, and set clear expectations about the evidence base.
What to expect: 4–6 week cycles tied to a specific injury or surgical recovery timeline.
Recovery Program →Strength & performance.
Lean mass retention during weight loss, training capacity, and supporting healthy growth hormone pulsatility.
Peptides we work with: CJC-1295 (no DAC), Ipamorelin, Sermorelin, Tesamorelin.
Growth-hormone-releasing peptides encourage pulsatile, physiologic GH release rather than the supraphysiologic levels of exogenous HGH. Paired with training and recovery, they support body composition — but they are not a substitute for either.
What to expect: 3–6 month cycles with IGF-1 monitoring.
Sleep & cognitive clarity.
Shallow sleep, poor recovery, brain fog, and age-related cognitive changes.
Peptides we work with: DSIP, Selank, Semax, Cerebrolysin (in select cases).
Sleep-focused peptides interact with HPA axis regulation. Nootropic peptides act on BDNF and related neurotrophic pathways. The evidence base is strongest in Eastern European clinical literature; we weight it accordingly and discuss the uncertainty openly.
Skin, hair & tissue.
Collagen synthesis, wound healing, hair density, and topical/systemic support for dermal health.
Peptides we work with: GHK-Cu, Thymosin Beta-4, Epithalon (select cases).
GHK-Cu in particular has a long dermatologic history in both topical and injectable forms. For hair, the mechanism is vascular and follicular, which means expectations should be appropriately calibrated against other interventions.
Immune & gut health.
Chronic immune dysregulation, post-viral recovery, gut barrier function, and autoimmune-adjacent presentations.
Peptides we work with: Thymosin Alpha-1, LL-37, BPC-157 (gut-focused).
Thymosin alpha-1 has decades of international clinical use for T-cell dysfunction. We do not treat autoimmune disease, but we do work alongside rheumatologists and primary care in specific immune-modulation scenarios.
Longevity & healthspan.
Biomarker optimization, mitochondrial function, senescence pathways, and sustained vitality with age.
Peptides we work with: Epithalon, MOTS-c, NAD+ (technically not a peptide but commonly grouped), Humanin analogs.
Longevity is the area of peptide medicine where we are most cautious. Animal data is frequently exciting, human data is frequently preliminary. We design longevity protocols around biomarkers you can actually measure and improve, not vague promises of life extension.
Sexual health & libido.
Desire, arousal, blood flow, and support for sexual dysfunction not resolved by hormone optimization alone.
Peptides we work with: PT-141 (bremelanotide), Kisspeptin-10.
PT-141 works centrally on melanocortin pathways, meaning it addresses desire rather than vascular function — a different mechanism from PDE5 inhibitors. It’s FDA-approved and prescribed on-label where appropriate.
Start a conversation. We’ll sort it out together.
Many patients come in with overlapping goals — better sleep, more energy, and some weight to lose. A consultation is how we untangle which mechanism is doing what, and where peptides actually help.
Book consultation